Security
INmune Bio Inc. Common stock · INMB
INMBNASDAQCommon stockCurrentCIK 1711754Updated Oct 30, 2026
INMB price & chart
Loading TradingView…
NASDAQ:INMB on TradingView ↗About the company
Inc. INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments for inflammation and immunology. The Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes. INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:
In the news
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases ↗
Recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
424B5 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
4 filing
3 filing
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01, 9.01
10-Q filing
Other Events
Items 8.01, 9.01
4 filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 33,358,000Source | 52,782,000Source | 26,845,000Source | 37,684,000Source | 52,453,000Source | 25,818,000Source | 37,801,000Source | 46,833,000Source | 32,351,000Source | 39,562,000Source | 57,001,000Source | 81,795,000Source |
| Property, Plant and Equipment, NetUSD | 878,000Source | — | 1,262,000Source | 706,000Source | — | 903,000Source | — | — | 955,000Source | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | — | 16,514,000Source | — | — | 16,514,000Source | — | 16,514,000Source | 16,514,000Source | — | 16,514,000Source | 16,514,000Source | 16,514,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 27,734,000Source | 33,552,000Source | — | 33,374,000Source | 31,069,000Source | — | 19,337,000Source | 26,002,000Source | 24,751,000Source | 20,922,000Source | 35,848,000Source | 52,153,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,704,000Source | 1,109,000Source | 4,413,000Source | 1,605,000Source | 3,143,000Source | 479,000Source | 1,283,000Source | — | 4,284,000Source | 1,181,000Source | — | — |
| Assets, CurrentUSD | 30,670,000Source | 35,851,000Source | 23,799,000Source | 36,034,000Source | 35,495,000Source | 22,822,000Source | 20,960,000Source | 29,824,000Source | 29,887,000Source | 22,662,000Source | 39,942,000Source | 64,675,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 472,000Source | 864,000Source | 621,000Source | 505,000Source | 1,013,000Source | 694,000Source | 207,000Source | 1,109,000Source | 595,000Source | 331,000Source | 1,510,000Source | 34,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,064,000Source | 335,000Source | 1,247,000Source | 374,000Source | 363,000Source | 1,410,000Source | 278,000Source | 389,000Source | 914,000Source | 307,000Source | 414,000Source | 507,000Source |
| Other Assets, NoncurrentUSD | 746,000Source | 82,000Source | 537,000Source | 570,000Source | 81,000Source | 683,000Source | 49,000Source | 106,000Source | 595,000Source | 79,000Source | 131,000Source | 99,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 7,980,000Source | 14,107,000Source | 6,483,000Source | 8,817,000Source | 15,373,000Source | 6,194,000Source | 8,128,000Source | 17,810,000Source | 8,827,000Source | 7,465,000Source | 18,862,000Source | 21,691,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 27,000Source | 22,000Source | 28,000Source | 27,000Source | 20,000Source | 27,000Source | 23,000Source | 18,000Source | 27,000Source | 22,000Source | 18,000Source | 18,000Source |
| Additional Paid in CapitalUSD | 229,888,000Source | 193,575,000Source | 237,688,000Source | 226,904,000Source | 178,767,000Source | 234,768,000Source | 203,103,000Source | 160,922,000Source | 233,271,000Source | 195,754,000Source | 159,143,000Source | 151,799,000Source |
| Retained Earnings (Accumulated Deficit)USD | -203,773,000Source | -153,886,000Source | -215,717,000Source | -197,301,000Source | -141,793,000Source | -214,444,000Source | -172,843,000Source | -132,047,000Source | -209,037,000Source | -163,104,000Source | -121,022,000Source | -91,014,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -764,000Source | -1,036,000Source | -823,000Source | -763,000Source | -713,000Source | -727,000Source | -610,000Source | -669,000Source | -737,000Source | -575,000Source | -799,000Source | -699,000Source |
| Stockholders' Equity Attributable to ParentUSD | 25,378,000Source | 38,675,000Source | 20,362,000Source | 28,867,000Source | 36,281,000Source | 19,624,000Source | 29,673,000Source | 28,224,000Source | 23,524,000Source | 32,097,000Source | 37,340,000Source | 60,104,000Source |
| Liabilities and EquityUSD | 33,358,000Source | 52,782,000Source | 26,845,000Source | 37,684,000Source | 52,453,000Source | 25,818,000Source | 37,801,000Source | 46,833,000Source | 32,351,000Source | 39,562,000Source | 57,001,000Source | 81,795,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 7,357,000Source | 13,823,000Source | 5,890,000Source | 8,586,000Source | 15,051,000Source | 5,388,000Source | 7,927,000Source | 17,450,000Source | 8,416,000Source | 7,221,000Source | 18,465,000Source | 10,918,000Source |
| Operating Lease, Liability, CurrentUSD | 457,000Source | 135,000Source | 812,000Source | 220,000Source | 130,000Source | 704,000Source | 146,000Source | 125,000Source | 623,000Source | 140,000Source | 119,000Source | 87,000Source |
| Operating Lease, Liability, NoncurrentUSD | 623,000Source | 284,000Source | 593,000Source | 231,000Source | 322,000Source | 806,000Source | 201,000Source | 360,000Source | 411,000Source | 244,000Source | 397,000Source | 526,000Source |
| Additional Financial Items | ||||||||||||
| Long-term DebtUSD | — | — | — | 15,000,000Source | — | — | 15,000,000Source | — | — | 15,000,000Source | — | 15,000,000Source |
| Long-term Debt, Current MaturitiesUSD | — | 2,494,000Source | — | — | 4,979,000Source | — | — | 7,455,000Source | — | — | 9,921,000Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | -27,299,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,497,000Source | 2,076,000Source | 9,910,000Source | 7,605,000Source | 7,368,000Source | 7,149,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -3,805,000Source | 102,000Source | 3,103,000Source | -724,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,403,000Source | -6,824,000Source | -22,582,000Source | -33,361,000Source | -11,980,000Source | -22,686,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -1,042,000Source | — | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 1,042,000Source | — | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 5,274,000Source | 27,612,000Source | 18,211,000Source | -4,225,000Source | 729,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,393,000Source | -1,585,000Source | 3,829,000Source | -14,926,000Source | -16,305,000Source | -22,657,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 27,734,000Source | 33,552,000Source | 18,411,000Source | 33,374,000Source | 21,358,000Source | 19,337,000Source | 24,751,000Source | 20,922,000Source | 35,848,000Source | 52,153,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | 1,690,000Source | 1,778,000Source | 1,372,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 10,000Source | -35,000Source | -159,000Source | 224,000Source | -100,000Source | -700,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,984,000Source | 1,719,000Source | 1,358,000Source | 1,534,000Source | 1,497,000Source | 2,076,000Source | 9,910,000Source | 7,605,000Source | 7,368,000Source | 7,149,000Source |
| DepreciationUSD | — | — | — | — | 100,000Source | — | 52,000Source | — | 84,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | — | — | 100,000Source | — |
| General and Administrative ExpenseUSD | — | — | 2,546,000Source | 2,219,000Source | 2,279,000Source | 2,253,000Source | 2,171,000Source | 2,316,000Source | 10,260,000Source | 9,483,000Source | 9,623,000Source | 9,258,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | 16,514,000Source | — | — | 16,514,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,472,000Source | -12,093,000Source | -1,273,000Source | -24,458,000Source | -5,407,000Source | -9,739,000Source | -45,933,000Source | -42,082,000Source | -30,008,000Source | -27,299,000Source |
| Nonoperating Income (Expense)USD | — | — | 961,000Source | 193,000Source | 203,000Source | 113,000Source | 405,000Source | 166,000Source | 1,450,000Source | 553,000Source | — | — |
| Operating ExpensesUSD | — | — | 7,433,000Source | 12,286,000Source | 1,476,000Source | 24,571,000Source | 5,812,000Source | 9,955,000Source | 47,433,000Source | 42,649,000Source | 29,896,000Source | 26,325,000Source |
| Operating Lease, ExpenseUSD | — | — | 134,000Source | 40,000Source | 206,000,000Source | 55,000,000Source | 147,000,000Source | 39,000Source | 381,000Source | 161,000Source | 163,000Source | 209,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 89,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | 166,000Source | — | 553,000Source | -267,000Source | — |
| Other Operating Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | -1,348,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 5,273,000Source | 27,544,000Source | 27,789,000Source | 775,000Source | 699,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 422,000Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | 50,000Source | 50,000Source | 14,000Source | 155,000Source | 374,000Source |
| Operating Income (Loss)USD | — | — | -7,433,000Source | -12,286,000Source | -1,476,000Source | -24,571,000Source | -5,812,000Source | -9,905,000Source | -47,383,000Source | -42,635,000Source | -29,741,000Source | -25,951,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | 166,000Source | — | 553,000Source | -267,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | 45,933,000Source | 42,082,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,472,000Source | -12,093,000Source | -1,273,000Source | -24,458,000Source | -5,407,000Source | -9,739,000Source | -45,933,000Source | -42,082,000Source | -30,008,000Source | -27,299,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.24Source | -0.6Source | -0.05Source | -1.05Source | -0.2Source | -0.43Source | -1.86Source | -2.11Source | -1.67Source | -1.52Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.24Source | -0.6Source | -0.05Source | -1.05Source | -0.2Source | -0.43Source | -1.86Source | -2.11Source | -1.67Source | -1.52Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 26,585,258Source | 20,185,676Source | 26,718,507Source | 23,298,455Source | 26,585,258Source | 22,496,191Source | 24,757,545Source | 19,944,304Source | 17,980,791Source | 17,927,327Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 26,585,258Source | 20,185,676Source | 26,718,507Source | 23,298,455Source | 26,585,258Source | 22,496,191Source | 24,757,545Source | 19,944,304Source | 17,980,791Source | 17,927,327Source |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | — | — | 100,000Source | — |
| General and Administrative ExpenseUSD | — | — | 2,546,000Source | 2,219,000Source | 2,279,000Source | 2,253,000Source | 2,171,000Source | 2,316,000Source | 10,260,000Source | 9,483,000Source | 9,623,000Source | 9,258,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 35,763,000Source | 22,603,000Source | — | — |
| Interest ExpenseUSD | — | — | — | 145,000Source | — | — | — | 0Source | — | 789,000Source | 2,278,000Source | — |
| Interest Expense, DebtUSD | — | — | — | 145,000,000Source | — | 250,000Source | — | — | 0Source | — | — | 2,014,000Source |
| Nonoperating Income (Expense)USD | — | — | 961,000Source | 193,000Source | 203,000Source | 113,000Source | 405,000Source | 166,000Source | 1,450,000Source | 553,000Source | — | — |
| Operating ExpensesUSD | — | — | 7,433,000Source | 12,286,000Source | 1,476,000Source | 24,571,000Source | 5,812,000Source | 9,955,000Source | 47,433,000Source | 42,649,000Source | 29,896,000Source | 26,325,000Source |
| Operating Lease, ExpenseUSD | — | — | 134,000Source | 40,000Source | 206,000,000Source | 55,000,000Source | 147,000,000Source | 39,000Source | 381,000Source | 161,000Source | 163,000Source | 209,000Source |
| Other ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 1,348,000Source |
| Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | 3,000Source | -3,000Source |
| Other Operating Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | -1,348,000Source |
| Research and Development ExpenseUSD | — | — | 4,887,000Source | 10,067,000Source | — | 5,804,000Source | 3,641,000Source | 7,639,000Source | 20,659,000Source | 33,166,000Source | 20,273,000Source | 17,067,000Source |
Filing attachments
ea030996701ex4-1.htm · 8-K · 2026-10-29
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TR…
Read attachment ↗ea030996701ex99-1.htm · 8-K · 2026-10-29
Exhibit 99.1 INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a definitive agreement with a single healthcare-focused, institutional investor for a registered direct offering of an aggregate of 3,000,000 shares of commo…
Read attachment ↗ea030922301ex99-1.htm · 8-K · 2026-10-21
Exhibit 99.1 INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Mast…
Read attachment ↗ea030922301ex99-2.htm · 8-K · 2026-10-21
Exhibit 99.2 INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027 Final pre-MAA package submitted to MHRA on October 20, 2026 ─────────────────────────────────────────────────────────────── Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeks ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗ea030540401ex99-1.htm · 8-K · 2026-09-14
EX-99.1 2 ea030540401ex99-1.htm PRESS RELEASE DATED SEPTEMBER 14, 2026 Exhibit 99.1 INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on i…
Read attachment ↗ea030006901ex99-1.htm · 8-K · 2026-07-31
EX-99.1 2 ea030006901ex99-1.htm PRESS RELEASE DATED JULY 31, 2026 Exhibit 99.1 INmune Bio Receives R&D Rebates of Approximately $4.6 Million BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research and development cash rebate from Australia of approximately $4.2 million. This rebate is in addition to approximatel…
Read attachment ↗